The pandemic has affected how new therapies are commercially launched. This has led to many life science manufacturers having to pivot to ensure patients are able to access the medications they need. Unprecedented times have led to them seeking a fresh approach and turning to Vynamic for support in planning and executing oncology launches.
In this case study, Vynamic assists two pharmaceutical companies in forming an alliance to launch two separate oncology products. Working both externally and internally, Vynamic mapped out four key changes to ensure both launches were successful from day one.
Vynamic also demonstrates how a brand can grow its share within the market two months post-approval through a coordinated and targeted virtual customer engagement plan and digital execution.
Read the full case study here.
Ashfield Engage, Vynamic and MicroMass deliver an integrated full contact centre solution.
Read moreAshfield Engage and MicroMass Communications deliver an outstanding patient experience strategy.
Read moreAshfield Engage announces the completion of the acquisition of Nuvera LLC, a US-based healthcare consulting firm.
Read moreA global medical company producing innovative skin regeneration treatments was looking for a customer service centre to support its products.
Read moreA medical company was looking for a dedicated customer service team and nurse medical information programme to support its gene therapy treatments.
Read moreHealth systems and their leaders are constantly faced with the challenge of becoming more efficient and innovative in their approach.
Read moreAshfield Excellence Academy, previously Ashfield Insight & Performance, has renamed to more clearly reflect its purpose.
Read more
Ben Beckley
Cell and gene therapies (C>s) continue to expand with 3,366 currently in preclinical and clinical development.
Read moreAshfield Engage, Vynamic and MicroMass deliver an integrated full contact centre solution
Read more